Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT01282424

Public ClinicalTrials.gov record NCT01282424. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Assess the Efficacy and Safety of Idelalisib in Subjects With Indolent B-Cell Non-Hodgkin Lymphomas Refractory to Rituximab and Alkylating Agents

Study identification

NCT ID
NCT01282424
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
125 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 17, 2011
Primary completion
May 1, 2018
Completion
May 15, 2018
Last update posted
Jul 10, 2019

2011 – 2018

United States locations

U.S. sites
22
U.S. states
15
U.S. cities
21
Facility City State ZIP Site status
St. Jude Medical Center Fullerton California 92835
Pacific Shores Medical Group Long Beach California 90813-3244
UCLA Los Angeles California 90095
Central Coast Medical Oncology Santa Maria California 93454
Stanford Cancer Center Stanford California 94035-5796
Collaborative Research Group, LLC Boynton Beach Florida 33435
Winship Cancer Institute Atlanta Georgia 30322-1013
Northwestern University Robert H. Lurie Comprehensive Cancer Center Chicago Illinois 60611
Washington University School of Medicine St Louis Missouri 63110
John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey 07601
University of Medicine and Dentistry of NJ New Brunswick New Jersey 08901-1914
Weill Cornell -New York Presbyterian Hospital New York New York 10002
Montefiore Medical Center New York New York 10467
The Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
University of Pennsylvania Philadelphia Pennsylvania 19104
South Carolina Oncology Associates Columbia South Carolina 29210
Chattanooga Hem/Oncology Ass (SCRI) Chattanooga Tennessee 37404
Sarah Cannon Research Institute Nashville Tennessee 37203
Charles A. Sammons Cancer Center Dallas Texas 75246
University of Virginia Medical Center Charlottesville Virginia 22908
Seattle Cancer Care Alliance Seattle Washington 98109
University of Wisconsin Madison Wisconsin 53792-5156

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01282424, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 10, 2019 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01282424 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →